

2019 Regular Session

HOUSE RESOLUTION NO. 291

BY REPRESENTATIVE DAVIS

MEDICAID: Requests the Louisiana Department of Health to study issues related to outpatient substance use treatment and providers

1 A RESOLUTION

2 To urge and request the Louisiana Department of Health to study the changes necessary to
3 increase access to outpatient substance use treatment, including medication-assisted
4 treatment (MAT), as well as recommendations for creating sustainable incentives
5 and supports for providers to serve as office-based opioid agonist treatment providers
6 and to report the findings of the study to the House Committee on Health and
7 Welfare on or before March 1, 2020.

8 WHEREAS, regular outpatient rehabilitation treatment focuses on providing patients
9 with access to care and support for addiction recovery in a nonresidential setting; and

10 WHEREAS, typically those entering outpatient substance abuse treatment have
11 already completed a residential program or received treatment through an intensive
12 outpatient or partial hospitalization treatment program or facility; and

13 WHEREAS, outpatient substance abuse treatment provides those recovering from
14 addiction with much-needed support as they transition back into their everyday lives; and

15 WHEREAS, relapse is most common right after an individual exits residential
16 treatment.

17 THEREFORE, BE IT RESOLVED that the Legislature of Louisiana does hereby
18 urge and request the Louisiana Department of Health to study the changes necessary to
19 increase access to outpatient substance use treatment, including medication-assisted
20 treatment (MAT), as well as recommendations for creating sustainable incentives and
21 supports for providers to serve as office-based opioid agonist treatment providers.

1 BE IT FURTHER RESOLVED the study shall consider all of the following:

2 (1) Preferred provider designation: establish a designation of high-quality
3 care for outpatient substance use disorder services. This designation should include
4 practices that, at a minimum, include a buprenorphine-waivered physician who can
5 prescribe buprenorphine and naltrexone in a variety of office-based practice settings
6 and opioid treatment providers, which have onsite partnerships with behavioral
7 health practitioners who provide counseling to patients receiving MAT.

8 (2) Payment for care coordination services: explore Medicaid reimbursement
9 for care coordination to preferred outpatient providers that provide buprenorphine
10 induction and maintenance and behavioral health counseling either onsite, or through
11 partnerships. Care coordinators should be expected to establish referral networks
12 with providers of all American Society of Addiction Medicine (ASAM) levels of
13 care, physical health providers, obstetrician-gynecologists, and to support patients
14 in accessing needed recovery supports. Also, explore Medicaid reimbursement for
15 care coordination to facilitate emergency department initiation of MAT and
16 transition to community-based care upon release.

17 (3) Evaluation of reimbursement rates: rates for services associated with
18 delivering MAT should be reviewed and compared to commercial rates. Rates for
19 assessment, induction, and maintenance, and behavioral health counseling should be
20 sufficient to encourage provider participation.

21 (4) Statewide provider education and outreach: provide education about
22 changes made to engage providers in the treatment of opioid use disorder. This shall
23 include training and outreach in partnership with local governing entities and
24 statewide provider associations that include MAT-specific courses, buprenorphine
25 waiver training, integration of the ASAM criteria, and establishing billing practices
26 for Medicaid reimbursement.

27 (5) Value-based purchasing: implementation of value-based purchasing in
28 the Medicaid managed care contracts to provide funding to hospitals that employ
29 case management teams or other measures to reduce substance use disorder-related
30 hospital readmissions.

1 BE IT FURTHER RESOLVED that the study be completed and a written report be
2 submitted to the House Committee on Health and Welfare on or before March 1, 2020.

3 BE IT FURTHER RESOLVED that a copy of this Resolution be transmitted to the
4 secretary of the Louisiana Department of Health.

DIGEST

The digest printed below was prepared by House Legislative Services. It constitutes no part of the legislative instrument. The keyword, one-liner, abstract, and digest do not constitute part of the law or proof or indicia of legislative intent. [R.S. 1:13(B) and 24:177(E)]

HR 291 Original

2019 Regular Session

Davis

Requests the Louisiana Department of Health to study issues related to outpatient substance use treatment and providers. Requests a written report to be submitted to the House Committee on Health and Welfare on or before Mar. 1, 2020.